Apoptosis-modulating proteins

Patent Citations (8)

Non-Patent Literature (53)

• Cazals-Hatem et al. Biochimica et Biophysica Acta 1132:109-113, Aug. 1992.Applicant
• Callard et al. The Cytokine FactsBook, Academic Press, London, p. 31, 1994.Applicant
• Bowie et al. Science 247:1306-1310, 1990.Applicant
• Ngo et al. The Protein Folding Problem and Tertiary Structure Prediction, Merz et al, eds, Birkhauser, boston, pp. 491-495, 1994.Applicant
• Wyllie, “Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation” Nature (1980) 284:555-556.Applicant
• Kanter et al., “Epidermal growth factor and tumor promoters prevent DNA fragmentation by different mechanisms” Biochem. Biophys. Res. Commun. (1984) 118:392-399.Applicant
• Duke et al., “IL-2 addiction: Withdrawal of growth factor activates a suicide program in dependent T cells” Lymphokine Res. (1986) 5:289-299.Applicant
• Tomei et al., “Inhibition of radiation-induced apoptosis in vitro by tumor promoters” Biochem. Biophys. Res. Commun. (1988) 155:324-331.Applicant
• Kruman et al., “Apoptosis of murine BW 5147 thymoma cells induced by dexamethasone and γ-irradiation” J. Cell. Physiol. (1991) 148:267-273.Applicant
• Ameisen et al., “Cell dysfunction and depletion in AIDS: The programmed cell death hypothesis” Immunol. Today (1991) 12:102-105.Applicant
• Sheppard et al., “The relationship between AIDS and immunologic intolerance” J. AIDS (1992) 5:143-147.Applicant
• Gerschenson et al., “Apoptosis: A different type of cell death” FASEB J. (1992) 6:2450-2455.Applicant
• Cohen et al., “Apoptosis and programmed cell death in immunity” Ann. Rev. Immunol. (1992) 10:267-293.Applicant
• Tsujimoto et al., “Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation” Science (1984) 226:1097-1099.Applicant
• Cleary et al., “Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation” Cell (1986) 47:19-28.Applicant
• McDonnell et al., “Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18)” Nature (1991) 349:254-256.Applicant
• Edgington, “Looking death in the eye: Apoptosis and cancer research” Biotechnol. (1993) 11:787-792.Applicant
• Sentman et al., “bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes” Cell (1991) 67:879-888.Applicant
• Strasser, “bcl-2 transgene inhibits T cell death and perturbs thymic self-cencorship” Cell (1991) 67:889-899.Applicant
• Hockenbery et al., “Bcl-2 functions in an antioxidant pathway to prevent apoptosis” Cell (1993) 75:241-251.Applicant
• Williams et al., “Molecular regulation of apoptosis: genetic controls on cell death” Cell (1993) 74:777-779.Applicant
• Zhu et al., “Systemic gene expression after intravenous DNA delivery into adult mice” Science (1993) 261:209-211.Applicant
• Veis et al., “Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair” Cell (1993) 75:229-240.Applicant
• Kiefer et al., “Molecular cloning of a new human insulin-like growth factor binding protein” Biochem. Biophys. Res. Commun. (1991) 176:219-225.Applicant
• Sanger et al., “DNA sequencing with chain-terminating inhibitors” Proc. Natl. Acad. Sci. USA (1977) 74:5463-5467.Applicant
• Boise et al., “bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death” Cell (1993) 74:597-608.Applicant
• Oltvai et al., “Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death” Cell (1993) 74:609-619.Applicant
• Zapf et al., “Isolation from adult human serum of four insulin-like growth factor (IGF) binding proteins and molecular cloning of one of them that is increased by IGF I administration and in extrapancreatic tumor hypoglycemia” J. Biol. Chem. (1990) 265:14892-14898.Applicant
• Feinberg et al., “A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity” Anal. Biochem. (1984) 137:266-267.Applicant
• Chen-Levy et al., “The bcl-2 candidate proto-oncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation” Mol. Cell. Biol. (1989) 9:701-710.Applicant
• Jacobson et al., “Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA” Nature (1993) 361:365-369.Applicant
• Monaghan et al., “Ultrastructural localization of BCL-2 protein” J. Histochem. Cytochem. (1992) 40:1819-1825.Applicant
• Lehrach et al., “RNA molecular weight determinations by gel electrophoresis under denaturing conditions, a critical reexamination” Biochem. (1977) 16:4743-4751.Applicant
• Thomas, “Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose” Proc. Natl. Acad. Sci. USA (1980) 77:5201-5205.Applicant
• Barr, “Expression of foreign genes in yeast” Transgenesis (1992) Murray, J.A.H., ed., Wiley & Sons, New York, pp. 55-79.Applicant
• Henderson et al., “Epstein-Barr virus-coded BHRF1 protein a viral homologue of Bcl-2, protects human B cells from programmed cell death” Proc. Natl. Acad. Sci. USA (1993) 90:8479-8483.Applicant
• Viegas-Péquignot, “In situ hybridization to chromosomes with biotinylated probes” In Situ Hybridization. A Practical Approach, D.G. Wilkinson, ed., IRL Press, Oxford, pp. 137-158.Applicant
• Pinkel et al., “Fluorescence in situ hybrization with human chromosome-specific libraries: Detection of trisomy 21 and translocations of chromosome 4” Proc. Natl. Acad. Sci. USA (1988) 85:9138-9142.Applicant
• McKearn et al., “Enrichment of hematopoietic precursor cells and cloning of multipotential B-lymphocyte precursors” Proc. Natl. Acad. Sci. USA (1985) 82:7414-7418.Applicant
• Nuñez et al., “Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines” J. Immunol. (1990) 144:3602-3610.Applicant
• Hockenbery et al., “Bcl-2 is an inner mitochondrial protein that blocks programmed cell death” Nature (1990) 348:334-336.Applicant
• Cherif et al., “Ordering markers in the region of the ataxia-telangiectasia gene (11q22-q23) by fluorescence in situ hybridization (FISH) to interphase nuclei” Hum. Genet. (1994) 93:1-6.Applicant
• Foroud et al., “Localization of an ataxia-telangiectasia locus to a 3-cM interval on chromosome 11q23: Linkage analysis of III families by an international consortium” Am. J. Hum. Genet. (1991) 49:1263-1279.Applicant
• Kapp et al., “Cloning of a candidate gene for ataxia-telangiectasia group D” Am. J. Hum. Genet. (1992) 51:45-54.Applicant
• Khati et al., “Genetic heterogeneity of autosomal dominant cerebellar ataxia type 1: Clinical and genetic analysis of 10 French families” Neurology (1993) 43:1131-1137.Applicant
• Meyn, “Ataxia-telangiectasia, apoptosis and cellular responses to DNA damage: A model” Cancer Genet. (1993) 53:(Abstract no. 1529).Applicant
• Orr et al., “Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1” Nature Genetics (1993) 4:221-226.Applicant
• Kennedy, “Prevention of carcinogenesis by protease inhibitors” Cancer Res. (1994) 54:1999s-2005s.Applicant
• Lam et al., “Evidence that BCL-2 represses apoptosis by regulating endoplasmic reticulum-associated Ca2+ fluxes” Proc. Natl. Acad. Sci. USA (1994) 91:6569-6573.Applicant
• Reed et al., “Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: Comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides” Cancer Res. (1990) 50:6565-6570.Applicant
• Yonehara et al., “A cell-killing monoclonal antibody (ANTI-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor” J. Exp. Med. (1989) 169:1747-1756.Applicant
• Hickish et al., “Ultrastructural localization of BHRF1: An Epstein-Barr virus gene product which has homology with bcl-2” Cancer Research (1994) 54:2808-2811.Applicant
• Tarodi et al., “Epstein-Barr virus BHRF1 protein protects against cell death induced by DNA-damaging agents and heterologous viral infection” Virology (1994) 201:404-407.Applicant